The short version of anti-doping fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-07-27. Anything still debated is marked as such rather than presented as settled.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Enzymes may be measured by the rate they change one coloured substance to another; in these tests, the results for enzymes are given as an activity, not as a concentration of the enzyme. Other tests use colorimetric changes to determine the concentration of the chemical in question. Turbidity may also be measured.
The various temperature rests favour the activity of different enzymes, depending on the type and modification level of the malt and the brewer's intentions. Of particular importance are α-amylase and β-amylase, which hydrolyse starch to produce dextrins and fermentable sugars such as maltose. A traditional step mash may include a β-glucanase and protein rest around 45 °C (113 °F), a β-amylase rest around 62 °C (144 °F), and an α-amylase rest around 70 °C (158 °F). With modern well-modified malts, the lower-temperature rests are often omitted, and mashing may begin directly at temperatures where the amylases are more active. β-glucanases break down β-glucans in the mash, while proteolytic enzymes break down proteins into smaller peptides and amino acids. In modern brewing, commercial β-glucanase preparations may also be added to the mash. During saccharification, a mash rest of around 65–71 °C (149–160 °F) is commonly used. Lower temperatures within this range favour β-amylase activity and generally produce a more fermentable wort, while higher temperatures favour α-amylase activity and generally produce a less fermentable wort containing more dextrins. Mash temperature, duration and pH therefore influence the carbohydrate composition and fermentability of the resulting wort.
In 2000, the company introduced a line of fair trade products. Of the approximately 300 million pounds (136 million kilograms) of coffee Starbucks purchased in 2006, about 18 million pounds (8.2 million kilograms) or 6% was certified as fair trade. Groups such as Global Exchange called for Starbucks to further increase its sales of fair trade coffees. After a long-running dispute between Starbucks and Ethiopia, Starbucks agreed to support and promote Ethiopian coffees. An article in BBC News, states that Ethiopian ownership of popular coffee designations such as Harrar and Sidamo is acknowledged, even if they are not registered. Ethiopia fought hard for this acknowledgement mainly to help give its poverty-stricken farmers a chance to make more money. In 2006, Starbucks said it paid $1.42 per pound ($3.1/kg) for its coffee, more than 33% higher than the commodity price at the time. However, the coffee Starbucks bought for $1.42 per pound ($3.1/kg), had a selling price—after transportation, processing, marketing, store rentals, taxes, and staff salary and benefits—of $10.99 per pound ($24.2/kg). As of 2013, the Starbucks website sells only one Ethiopian coffee. In addition, Starbucks is an active member of the World Cocoa Foundation, although targets set in 2005, 2008 and 2010 to reduce child labor that the Foundation has backed have consistently not been met.
== Synthesis == PreproGRP begins with signal peptidase cleavage to generate the pro-gastrin-releasing-peptide (proGRP), which is then processed by proteolytic cleavages, to form smaller GRP peptides. These smaller peptides are released by the post-ganglionic fibers of the vagus nerve, which innervate the G cells of the stomach and stimulate them to release gastrin. GRP regulates numerous functions of the gastrointestinal and central nervous systems, including release of gastrointestinal hormones, smooth muscle cell contraction, and epithelial cell proliferation.
=== Legal status === Eflornithine, sold under the brand name Vaniqa, was granted marketing approval by the US FDA, the European Commission among others, is a topical prescription treatment that slows the growth of facial hair. Ornidyl, the injectable form of eflornithine hydrochloride, is licensed by Sanofi-Aventis, and is discontinued in the US. In July 2025, Norgine B.V. withdrew its application in the European Union for a marketing authorization of Ifinwil for the treatment of people with high-risk neuroblastoma (cancer of nerve cells in different parts of the body).
Sources: en.wikipedia.org
=== 1987 === January 16: Natives within the Party who oppose his policies of economic redevelopment (Perestroika). It is Gorbachev's hope that through initiatives of openness, debate and participation, that the Soviet people will support Perestroika. February 25: Phosphorite War breaks out in Estonia. April 15: An insurrection occurred in Sri Lanka by the Marxist–Leninist group, JVP. June 12: During a visit to West Berlin, U.S. President Ronald Reagan challenges Soviet General Secretary Mikhail Gorbachev in a speech: "Mr. Gorbachev, tear down this wall!" (The Berlin Wall). June 15: Famous Italian Singer and Songwriter Adriano Celentano lands in Moscow to present his movie Joan Lui in Soviet theaters, another step that opens the Soviet world to the Western one. September 10: The Battle of Cuito Cuanavale, Angola begins and further intensifies the South African Border War. September 30: Mohammad Najibullah becomes President of Afghanistan and implements a policy of National Reconciliation as a means of putting an end to the Soviet–Afghan War as well as beginning an end to Soviet influence in the country. December: A short war was fought between Thailand and Laos. December 8: The Intermediate-Range Nuclear Forces Treaty is signed in Washington, D.C. by U.S. President Ronald Reagan and Soviet leader Mikhail Gorbachev. Some later claim this was the unofficial beginning of the end of the Cold War. Gorbachev agrees to START I treaty. December 9: The First Intifada was waged by Palestinians against the Israeli government.
Sales caps are also placed on the properties of the CLT to maintain affordability for generations of future buyers. Most of the skepticism surrounding CLTs is rooted in their reliance on external funding. As CLT organizations grow and their boards become more professionalized, they are often distanced from their original ideals of community-based land control which the organizations were founded upon. Most CLTs are not built upon economically self-sustaining models, so they are forced to compete for external funding, taking away the CLT's autonomy, as all of the power is transferred into the hands of grant-funding organizations and private foundations. This problem could be avoided if CLTs could somehow source their funding from community investors or funders who share their ideals of community empowerment.
The surgeon cuts the cartilage portion of the hump with a scalpel, and chisels the bone portion with an osteotome (bone chisel). After chiselling away the main mass of the nasal hump with an osteotome, the surgeon then sculpts, refines, and smoothens the cut nasal bones with rasps (files).
== Species distribution == BHBDH is found in dogfish sharks (Squalus acanthias) rectal glands and has been found to have a large increase in activity in activity after feeding. The largest and most significant peak of BHBDH activity occurred 4–8 hours in the rectal glands of the sharks. Besides dogfish, this enzyme is found in a large range of organisms all the way from unicellular organisms to higher order primates such as humans. In humans, this enzyme is used medically in diabetes patients to detect ketone bodies which are associated with diabetic ketoacidosis. This is by no means an exhaustive list of organisms where BHBDH is found, these organisms are merely some of the common examples of this enzyme in action.
== Diagnosis == The clinical definition of ordinary smallpox is an illness with acute onset of fever followed by a rash characterized by firm, deep-seated vesicles or pustules in the same stage of development without other apparent cause. Before the availability of laboratory testing, doctors could diagnose smallpox by touch alone, due to the distinctively hard pustules. Microscopically, poxviruses produce characteristic cytoplasmic inclusion bodies, the most important of which are known as Guarnieri bodies, and are the sites of viral replication. Guarnieri bodies are readily identified in skin biopsies stained with hematoxylin and eosin, and appear as pink blobs. They are found in virtually all poxvirus infections but the absence of Guarnieri bodies could not be used to rule out smallpox. The diagnosis of an orthopoxvirus infection can also be made rapidly by electron microscopic examination of pustular fluid or scabs. All orthopoxviruses exhibit identical brick-shaped virions by electron microscopy. Definitive laboratory identification of variola virus involved growing the virus on chorioallantoic membrane (part of a chicken embryo) and examining the resulting pock lesions under defined temperature conditions. Strains were characterized by polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) analysis. Serologic tests and enzyme linked immunosorbent assays (ELISA), which measured variola virus-specific immunoglobulin and antigen were also developed to assist in the diagnosis of infection.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.